Rational use of insulin analogues in the treatment of type 1 diabetic children and adolescents: personal experience;Utilisation rationnelle des nouveaux analogues de l'insuline dans le traitement du diabète de type 1 chez les enfants et adolescents : expérience personnelle

Archives de Pediatrie

Volumn 13, Issue 9, 2006, Pages 1275-1282

  Dorchy, H ^a  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Childhood diabetes; Insulin analogues; Insulin treatment

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LONG ACTING INSULIN;

ADOLESCENT; ARTICLE; CHILD; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; QUALITY OF LIFE;

ADOLESCENT; CHILD; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 33748310589     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2006.06.015     Document Type: Article

References (40)

1. Schoenle E.J., Schoenle D., Molinari L., et al. Impaired intellectual development in children with type I diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia 45 (2002) 108-114
2. Dorchy H., and Olinger S. Bien-être des diabétiques insulinodépendants. Évaluation chez 100 adolescents et adultes jeunes en fonction de leur contrôle métabolique. Presse Med. 26 (1997) 1420-1424
3. Hoey H., Aanstoot H.J., Chiarelli F., Daneman D., Danne T., Dorchy H., et al. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care 24 (2001) 1923-1928
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
5. Verougstraete C.M., Libert J.A., and Dorchy H.R. Discordant diabetic retinopathy in homozygous twins: the importance of good metabolic control. J. Pediatr. 134 (1999) 658
6. Dorchy H. Screening for subclinical complications in young type 1 diabetic patients: experience acquired in Brussels. Pediatr. Endocrinol. Rev. 1 (2004) 380-403
7. Coulon J., Willems D., and Dorchy H. Augmentation de la concentration plasmatique de la protéine-C-réactive dans le diabète de l'enfant et de l'adulte jeune. Presse Med. 34 (2005) 89-93
8. Dorchy H. Quel contrôle glycémique peut être obtenu chez des jeunes diabétiques sans sécrétion résiduelle d'insuline endogène ? Quelle est la fréquence des hypoglycémies sévères et des complications subcliniques ?. Arch. Pediatr. 1 (1994) 970-981
9. Dorchy H., Roggemans M.P., and Willems D. Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: a Belgian experience. Diabetes Care 20 (1997) 2-6
10. Dorchy H. Insulin regimens and insulin adjustments in diabetic children, adolescents and young adults: personal experience. Diabetes Metab. 26 (2000) 500-507
11. Dorchy H. Sport et diabète de type 1: expérience personnelle. Rev. Med. Brux. 23 (2002) A211-A217
12. Dorchy H. Dietary management for children and adolescents with diabetes mellitus: personal experience and recommendations. J. Pediatr. Endocrinol. Metab. 16 (2003) 131-148
13. Dorchy H. Prise en charge des diabètes des enfants et des adolescents : expérience personnelle. Rev. Med. Brux. 26 (2005) S46-S54
14. Bolli G.B. Rational use of insulin analogues in the treatment of type 1 diabetes mellitus. Pediatr Endocrinol Rev 1 (2003) 9-21
15. Derr R., Garrett E., Stacy G.A., et al. Is HbA(1c) affected by glycemic instability?. Diabetes Care 26 (2003) 2728-2733
16. Hillman N., Herranz L., Grande C., et al. Is HbA(1c) influenced more strongly by preprandial or postprandial glycemia in type 1 diabetes?. Diabetes Care 25 (2002) 1100-1101
17. Heine R.J., Balkau B., Ceriello A., et al. What does postprandial hyperglycaemia mean?. Diabet. Med. 21 (2004) 208-213
18. Mc Carter R.J., Hempe J.M., Gomez R., et al. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 27 (2004) 1259-1264
19. Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia 47 (2004) 1143-1148
20. Duchateau J., Schreyen H., and Dorchy H. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro. Diabete Metab. 18 (1992) 272-276
21. Ostergaard J., Hansen T.K., Thiel S., et al. Complement activation and diabetic vascular complications. Clin. Chim. Acta 361 (2005) 10-19
22. Dimitriadis G.D., and Gerich J.E. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 6 (1983) 374-377
23. Homko C., Deluzio A., Jimenez C., et al. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 26 (2003) 2027-2031
24. Heinemann L., Weyer C., Rauhaus M., et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 21 (1998) 1910-1914
25. Danne T., Aman J., Schober E., et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 26 (2003) 2359-2364
26. Mortensen H.B., Robertson K.J., Aanstoot H.J., et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidøre Study Group on Childhood Diabetes. Diabet. Med. 15 (1998) 752-759
27. Heise T., Nosek L., Ronn B.B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
28. Mortensen H.B., and Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. Hvidøre Study Group on Childhood Diabetes. Diabetes Care 20 (1997) 714-720
29. The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 11 (1988) 567-573
30. Standl E., Lang H., and Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol. Ther. 6 (2004) 579-588
31. Hennige A.M., Sartorius T., Tschritter O., et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 49 (2006) 1274-1282
32. Ratner R.E., Hirsch I.B., Neifing J.L., et al. Less hypoglycemia with insulin glargine in intensive therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23 (2000) 639-643
33. Vague P., Selam J.-L., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
34. ®). Rev. Med. Brux. 27 (2006) 89-94
35. Kurtzhals P., Schäffer L., Sorensen A., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (2000) 999-1005
36. Home P.D., and Ashwell S.G. An overview of insulin glargine. Diabetes Metab. Res. Rev. 18 Suppl 3 (2002) S57-S63
37. Lievre M., Marre M., Robert J.J., et al. Cross-sectional study of care, socioeconomic status and complications in young French patients with type 1 diabetes mellitus. Diabetes Metab. 31 (2005) 41-46
38. Gay C.L., Chapuis F., Bendelac N., et al. Reinforced follow-up for children and adolescents with type 1 diabetes and inadequate glycaemic control: a randomized controlled trial intervention via the local pharmacist and telecare. Diabetes Metab. 32 (2006) 159-165
39. Dorchy H. Dorchy's recipes explaining the "Intriguing efficacity of Belgian conventional therapy". Diabetes Care 17 (1994) 458-460
40. Polonsky K.S., Given B.D., Hirsch L.J., et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 318 (1988) 1231-1239